Funded Startups in Ann Arbor
Ann Arbor's funding activity across these 50 rounds spans September 2021 through July 2025, with biotechnology and artificial intelligence accounting for t…
Ann Arbor's funding activity across these 50 rounds spans September 2021 through July 2025, with biotechnology and artificial intelligence accounting for the heaviest deal flow. Biotech is the dominant sector — represented by ONL Therapeutics ($65M Series D, September 2024), Akadeum Life Sciences ($20M, June 2025), Esperion ($225M Post-IPO Equity, December 2021), and roughly eight additional companies. A separate cluster of AI and data companies includes ADASTEC, Voxel51 ($30M Series B, May 2024), Censys ($35M Series B, January 2022), and SkySpecs ($20M, March 2025). Health care rounds — including Workit Health ($90M Series C, October 2021) and Amplitude Vascular Systems ($36M Series B, January 2025) — represent a third concentration. A substantial share of rounds carry no disclosed amount or are labeled Series Unknown, making stage and size comparisons approximate across the full set.
Most recent rounds
50 shownRelated listings
Frequently asked
What are the largest disclosed rounds among Ann Arbor startups in this dataset?
The top five by disclosed amount are Esperion ($225M Post-IPO Equity, December 2021), May Mobility ($105M Series D, November 2023), Workit Health ($90M Series C, October 2021), ONL Therapeutics ($65M Series D, September 2024), and Optilogic ($40M Series B, April 2025).
Which sectors are most active in Ann Arbor funding?
Biotechnology is the most represented sector, with 11 companies including Esperion, ONL Therapeutics, Akadeum Life Sciences, HYGIEIA, and Upkara. Health care accounts for six companies and AI for five, while data and analytics, information technology, and financial services each contribute smaller clusters.
How many Ann Arbor rounds closed in 2025?
Seven rounds closed through July 2025: Amplitude Vascular Systems ($36M Series B, January), SkySpecs ($20M, March), Optilogic ($40M Series B, April), MemryX (undisclosed, May), Akadeum Life Sciences ($20M, June), Spike Neuro ($3M, June), and ADASTEC ($3M, July).
What funding stages appear most often in this Ann Arbor data?
Series Unknown is the most common label across the 50 rounds. Among named stages, Series B appears six times — Optilogic, Amplitude Vascular Systems, Censys, Voxel51, Blumira, and HYGIEIA — while Seed appears five times (Blackwell Security, Tandem, Glacier Cannabis, SensCy, Tenacity) and Series D twice, covering May Mobility and ONL Therapeutics.
How many rounds in this dataset have undisclosed amounts, and what is the disclosed range?
Twelve of the 50 rounds list no disclosed amount, including MemryX, Derq, TRAILS, Tropolis, and BioVigil. Among rounds with figures, sizes range from $10K (Warmilu, August 2023) to $225M (Esperion, December 2021), with most disclosed deals falling between $2M and $40M.
What non-traditional round types appear in the Ann Arbor data?
Two rounds are classified as Post-IPO Equity — Esperion ($225M, December 2021) and Endra ($9M, April 2022). Two Grant rounds also appear: Newhaptics ($2M, September 2022) and Merit Network (undisclosed, June 2022). Franworth received Private Equity funding (undisclosed, May 2022), and LeaseMagnets closed a Pre-Seed round of $100K in September 2021.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.